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Summary
Objective: We sought to determine whether sequence variations in cartilage collagen genes are associated with primary, early-onset
osteoarthritis (OA).
Methods: The cartilage collagen genes, COL2A1, COL9A1, COL9A2, COL9A3, COL11A1 and COL11A2, were screened for sequence
variations in 72 Finnish probands and one US family with primary early-onset hip and/or knee OA. In addition, allelic association studies were
performed using six to 12 common polymorphisms from each gene by genotyping 72 OA patients and 103 controls.
Results: Altogether 239 sequence variations were found, of which 16 were not present in the controls. Seven of the unique variations, four in
COL11A1, two in COL11A2 and one in COL2A1, were studied further, because they resulted in the substitution of conserved amino acids or
were predicted to affect mRNA splicing. Co-segregation of a sequence variation and the phenotype was found in all four families available for
study. Association analysis failed to identify any common predisposing alleles.
Conclusions: Early-onset OA demonstrates locus and allelic heterogeneity since the identiﬁed variations were in three different collagen
genes and each of the six probands had a different mutation. It is also possible that some OA cases represent the mild end of the
chondrodysplasia phenotypic spectrum. The major susceptibility alleles in this form of OA, however, remain to be identiﬁed.
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Repair
SocietyIntroduction
Osteoarthritis (OA) is the most common musculoskeletal
disease in developed countries1. It is characterised by
progressive degradation of articular cartilage that leads to
joint space narrowing, subchondral sclerosis, osteophyte
and cyst formation, and eventually loss of joint function2,3.
While OA can develop secondary to various factors, the
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Received 14 June 2004; revision accepted 6 February 2005.497majority of cases are considered primary3. Certain forms of
OA have long been known to have a genetic component4e6,
and recent studies have conﬁrmed these ﬁndings and
indicated a signiﬁcant role for genetic factors in primary
OA1,7,8. Even though numerous variations in multiple genes
have been suggested to cause increased risk of OA, the
results from these studies have not been consistently
replicated8.
Hyaline cartilage consists of relatively few cells, chon-
drocytes, but an abundant extracellular matrix consisting
mainly of collagens. Collagen II, which makes up about
50% of the organic matrix9e11, is a homotrimer of three
a1(II) chains and is encoded by the COL2A1 gene, while
the minor cartilage collagens, types IX and XI, are
heterotrimeric molecules consisting of three different
a chains each. The collagen IX a chains, a1(IX), a2(IX),
and a3(IX), are encoded by the COL9A1, COL9A2, and
COL9A3 genes, and the collagen XI a chains, a1(XI),
a2(XI), and a3(XI), by the COL11A1, COL11A2 and
COL2A1 genes, respectively12,13.
Mutations in COL2A1 can result in chondrodysplasias
(CD) associated with early-onset OA. A cysteine519 for
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OA and only mild CD14e17, and a Cys75Arg substitution in
three families with OA and mild spondyloepiphyseal
dysplasia18e20. The role of COL2A1 in OA is further
supported by linkage21,22 and some association stud-
ies23e25. However, most COL2A1 mutations have been
shown to result in severe CDs, not OA13,26,27.
Mutations in collagen IX genes have been shown to
cause multiple epiphyseal dysplasia (MED), a relatively mild
CD characterised mainly by knee OA in adult patients28e35.
Further support for the possible role of collagen IX in OA
has been obtained from animal studies. Mice lacking the
a1(IX) chains36 and transgenic mice heterozygous for
a large in-frame deletion of Col9a137 developed degener-
ative joint disease similar to human OA. In addition,
a suggestive linkage has been reported between COL9A1
and hip OA in female patients38. Mutations in the collagen
XI genes COL11A1 and COL11A2 have also been shown to
result in relatively mild CDs associated with OA13,39e41. A
recent study indicated that heterozygosity for a loss-of-
function mutation in Col11a1 resulted in the development of
OA in the knee joints and temporomandibular joints of
heterozygous cho/C mice42.
Because of the evidence suggesting a role for cartilage
collagens in OA, we performed a mutation and association
analysis ofCOL2A1,COL9A1,COL9A2,COL9A3,COL11A1
and COL11A2 in probands with primary hip and/or knee OA.
Subjects and methods
PATIENTS AND CONTROLS
A North American family (EC; Fig. 1) with early-onset OA
was referred to us for mutation analysis. Clinical data and
blood samples were obtained from the family members.
Seventy-two unrelated Finnish probands with early-onset
hip and/or knee OA from the Departments of Orthopaedics
at Jyva¨skyla¨ Central Hospital (J1 to J64) and Kuopio
University Hospital (K97 to K146) in central Finland, located
only about 90 miles apart, were included in the study. All
these probands were examined clinically and radiologically,
their diagnosis was conﬁrmed according to Altman43, and
they were further selected on the following criteria: (1) age
at onset of OA symptoms %50 years, (2) OA affecting at
least two joints, or (3) one joint disease and a positive family
history or an age at onset less than 40 years, (4) body mass
index (BMI) less than 30, and (5) a negative trauma history.
Seventy-two of the initial 116 probands, 33 females and 39
males with a mean age at onset of OA symptoms of 39.7
(G9.1) years, met the selection criteria. Forty-two of them
had hip OA, 21 knee OA and nine both hip and knee OA,
and they had all undergone at least one hip or knee
arthroplasty or other open or arthroscopic surgery of the
knee joint (Table I). The radiographs of the Finnish cohort
were evaluated by two expert clinicians blinded to the
results of the genetic data.
Altogether 103 unrelated controls were obtained; 50
controls were from Jyva¨skyla¨ Central Hospital and 53 from
Kuopio University Hospital. Forty-seven of these were
females and 56 were males. They were all over 45 years
of age (mean 57G 9 years) and had no history or
symptoms of OA. They were not examined clinically or
radiologically. The presence of some nucleotide variations
was also analysed in a random population sample of 100
adult Finnish individuals. The random population was
screened to further conﬁrm that the observed sequence
variations were not just rare polymorphisms.The study design was approved by the local ethical
committees and informed consent was obtained from all the
subjects.
MUTATION ANALYSIS
Genomic DNA was isolated from EDTA-anti-coagulated
blood and screened for sequence variations by the confor-
mation sensitive gel electrophoresis (CSGE) method44.
Sequences corresponding to all 52 exons of the COL2A1
gene45, all 38 exons ofCOL9A146, all 32 exons ofCOL9A246,
31 out of the 32 exons (exons 2e32) of COL9A347, all 66
exons of COL11A248, all 68 exons of COL11A1 gene40 and
the corresponding exon ﬂanking sequences were ampliﬁed
by polymerase chain reaction (PCR) to obtain products of
182 bp to 487 bp and each sample was analysed on CSGE
gel as described earlier to reveal possible sequence
variations44, with the exception that the gels were stained
with SYBR Gold nucleic acid gel stain (Eugene, USA)
instead of ethidium bromide. PCR products that showed new
or obscure patterns on the CSGE gels were sequenced with
an ABI PRISM 377 or 3100 Sequencer and BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems) to
identify underlying sequence variations.
RNA ANALYSIS
Total RNA was extracted (TRIzol LS Reagent,
Gibco BRL) from Epstein-Barr virus (EBV)-transformed
Fig. 1. Family pedigree of the North American family and CSGE
analysis of exon 43 in the COL11A2 gene. Black circles (females)
and squares (males) indicate individuals with radiologically
conﬁrmed OA. The proband is marked with a diagonal arrow.
Three alleles were found in exon 43 by CSGE: A, a polymorphic A
nucleotide in the CCA codon; B, a polymorphic G nucleotide in the
CCG codon; and C, a deletion of A in IVS422 and an A nucleotide
in the CCA codon. Heteroduplexes generated by these alleles are
indicated.
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Characteristics of Finnish OA patients
Patient/
gender
Age
of
onset/age*
Affected
joints
Operations
Knee Hip
j1 (m) 40/63 H: l.a AP l.a.
j3 (f) 35/46 H: l.a AP dx
j4 (m) 48/54 H: l.a AP sin
j6 (m) 38/66 H: l.a Ap dx
j7 (f) 15/37 K: l.a AS l.a,
OT sin
j8 (f) 45/72 H: dx AP dx
j10 (m) 35/54 H: l.a AP l.a.
j11 (m) 20/68 K: l.a,
H: sin
AP sin
j14 (m) 40/50 H: sin AP sin
j15 (m) 20/61 H: dx AP dx
j16 (f) 45/62 K: l.a AP l.a.
j19 (f) 48/61 H: l.a AP l.a.
j20 (f) 20/50 H: sin AP sin
j21 (m) 45/68 K: l.a OT dx,
AP sin
j24 (f) 50/66 H: l.a AP l.a.
j28 (m) 30/53 K: l.a AS l.a,
OT l.a
j29 (f) 30/46 K: l.a AS l.a
j32 (f) 40/50 K: dx AS dx
j33 (f) 40/64 H: l.a AP dx
j35 (f) 30/61 H: dx AP dx
j37 (f) 30/59 H: l.a AP l.a.
j38 (m) 38/64 H: l.a AP l.a.
j39 (m) 38/59 H: dx AP dx
j40 (f) 40/53 H: dx AP dx
j41 (m) 26/60 K: l.a,
H: l.a
AP l.a
j42 (m) 17/62 K: l.a,
H: l.a
AP dx AP l.a.
j43 (f) 45/64 H: l.a AP l.a
j44 (m) 49/65 H: l.a AP l.a.
j45 (f) 43/45 K: l.a AS l.a
j46 (m) 27/47 K: l.a AS l.a
j47 (m) 41/61 H: l.a AP l.a.
j49 (f) 45/61 K: l.a,
H: l.a
AP sin
j50 (m) 43/71 H: dx AP dx
j51 (m) 26/65 H: l.a AP sin
j54 (m) 30/68 K: sin,
H: dx
AP sin AP dx
j56 (m) 42/55 H: l.a AP dx
j58 (m) 35/57 K: l.a,
H: dx
AP l.a. AP dx
j59 (m) 35/69 H: sin AP sin
j60 (m) 44/60 H: l.a AP sin
j61 (f) 20/47 K: l.a AS dx
j64 (m) 40/70 H: sin AP sin
K97 (f) 50/54 K: l.a. AS sin
K102 (f) 38/51 K: l.a. AS sin,
AP dx
K103 (m) 50/60 H: l.a. OT sin.
K104 (f) 49/57 K: dx AS, OT dx
K107 (m) 50/62 H: l.a. AP l.a.
K108 (f) 44/58 K: l.a. AP l.a
K110 (f) 39/50 H: l.a. OT sin,
AP l.a.
K112 (f) 50/62 K: dx,
H: dx
AS dx,
OT dx
AP dx.
K113 (m) 48/56 K: sin,
H: dx
AP dx.
K115 (f) 39/55 K: l.a. AS l.a
K117 (m) 50/61 K: l.a. AS sin
K118 (f) 49/60 H: l.a. AP l.a.
K122 (m) 35/57 K: sin AS sinlymphoblasts of a North American (subject II:2; Fig. 1) and
a Finnish individual (proband J35) and used as a template
for reverse transcription polymerase chain reaction
(RT-PCR). The ﬁrst strand was synthesised using an
oligo(dT) primer (Superscript Preampliﬁcation System,
Gibco BRL). Regions corresponding to exons 39 and 47
of the COL11A2 gene and exons 35 to 41 of the COL2A1
gene were ampliﬁed by PCR from the complementary
DNAs (cDNAs) of individual II:2 and proband J35, re-
spectively. The ﬁrst and second PCRs were performed with
the same primers in the case of COL11A2 cDNA, and the
second PCR with the nested primers corresponding to
exons 36 and 40 in the case of COL2A1 cDNA. The PCR
products of the COL11A2 cDNA were analysed on agarose
gels, cloned and sequenced, while those of the COL2A1
cDNA were analysed on agarose gels and sequenced
directly with the RT-PCR primers and nested sequencing
primers from exons 37 and 39.
GENOTYPING
Single nucleotide polymorphisms (SNP) or small in-
sertion/deletion polymorphisms that were initially detected
here as heteroduplexes in CSGE analysis were genotyped
in the 72 unrelated Finnish probands and 103 controls. Six
to 12 relatively common polymorphisms were selected from
each gene for allelic association studies and analysed as
indicated in supplemental table. The locations of the
polymorphisms are shown in Fig. 2.
STATISTICAL ANALYSIS
The computer program Polyphen was used to predict
whether observed amino acid substitutions were likely to be
pathogenetic49e51.
Table I (continued)
Patient/
gender
Age
of
onset/age*
Affected
joints
Operations
Knee Hip
K123 (m) 48/61 H: l.a. AP l.a.
K124 (m) 44/59 K: l.a. AS l.a
K125 (m) 43/60 H: l.a. OT sin,
AP l.a.
K126 (f) 40/48 K: l.a. AS sin
K127 (m) 40/55 K: dx AS dx
K128 (m) 50/62 H: l.a. AP l.a.
K129 (m) 48/60 H: sin OT sin
K130 (f) 37/56 H: l.a. OT sin
K131 (m) 35/62 H: l.a. AP dx
K133 (f) 40/56 K: l.a. OT l.a
K134 (m) 40/63 H: l.a. AP l.a.
K135 (f) 48/57 H: dx OT dx
K136 (m) 50/59 K: l.a. AS dx
K137 (f) 50/58 K: dx AS dx
K138 (f) 50/60 H: sin OT,
AP sin.
K139 (f) 47/61 H: l.a. OT,
AP dx.
K141 (f) 47/61 H: dx OT,
AP dx.
K146 (m) 45/58 K: l.a.,
H: l.a.
OT dx
fZ female, mZmale, HZ hip, KZ knee, sinZ left, dxZ right,
l.a.Z both left and right, ASZ artroscopy, OTZ osteotomy,
APZ arthroplasty, SVZ synovectomy.
*Age at the time of inclusion to the study.
500 E. Jakkula et al.: Cartilage collagens and osteoarthritisFig. 2. Schematic presentation of the locations of the polymorphisms used in the association analysis. The genes are drawn to scale. The
location of each polymorphism is indicated by a vertical line. The distance between the polymorphisms is shown above each gene, and the
polymorphisms are indicated below each gene (see Table III). *The exact sizes of introns 2 and 4 in COL11A1 were not available but
the distance of the ﬁrst analysed SNP from the 5#-end of the gene was estimated to be over 90 kb.The observed allele frequencies for all the genotyped
polymorphisms were compared between the cases and
controls. Fisher’s ‘‘exact’’ test was used for the analysis of
individual diallelic polymorphisms, one polymorphism at
a time.
Joint analysis of all polymorphisms within a gene was
performed using the Dismult computer program, which
implements a multiple two-point approach for linkage
disequilibrium analysis52.
Results
FAMILY STUDY
A small US family with early-onset OA was referred to us
for mutation analysis (Fig. 1). The proband had had hip and
knee pain and stiffness since her 20s and had underwent
bilateral hip (right hip at the age of 49 years, left hip at 51
years) and knee replacements (at the age of 55 years) and
surgical correction of the right thumb was performed at the
age of 57 years. She had near-normal vision, but had
developed hearing loss with advancing age. Her daughter
had no symptoms of OA or hearing or vision problems at the
age of 48 years, but her son, currently 44 years of age, has
experienced knee pain since age 17, after participating in
athletic activities. At 33 years, he underwent right kneearthroscopic surgery to treat damaged cartilage. He was of
normal stature (183 cm) without any evidence of dispropor-
tion, and although there was mild nasal anteversion, mild
myopia and mild sensorineural hearing loss, these features
were not as severe as in Stickler syndrome. Radiographs of
the knees and cervical spine revealed OA, without evidence
of CD (not shown). Radiographs of the hands and hips were
normal (not shown).
Analysis of COL11A2 identiﬁed deletion of nucleotide A
(c.31512) at the 3#-splice site of intron 42 (data not
shown) in both affected family members (Fig. 1) which was
absent from 100 US random population samples, 103
Finnish controls and 100 Finnish random population
samples. RT-PCR analysis of RNA prepared from lympho-
cytes of the proband’s son revealed two bands of about
750 bp and 650 bp (data not shown). Sequencing indicated
that the longer PCR product corresponded to the wild-type
allele, while the shorter one lacked sequences for exon 43
and thus had an in-frame deletion of 108 bp, or 36 amino
acids (not shown).
MUTATION ANALYSIS OF OA PROBANDS
Seventy-two Finnish probands with primary early-onset
hip and/or knee OA were screened by CSGE for mutations
in the six genes coding for collagens II, IX and XI. All
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Sequence variations unique to the OA patients
Gene Location Nucleotide variation Predicted consequence Proband
COL2A1 E37 c.2574COT Gly658Gly (NKy) K136
E38 c.2659GOA* decreased mRNA level J35
COL9A1 IVS14 c.1144C24TOC NK J14
IVS17 c.1287C60_64delCTTTA NK J3
COL9A2 IVS30 c.1793112_114delTCT NK J51
COL9A3 IVS13 c.684C69AOG NK K137
IVS14 c.73918COG NK K113
E30 c.1773COT Asp591Asp (NK) K115
COL11A1 E2 c.139TOA* Phe482Ile K123
E8 c.1021GOC* Glu188Gln J14
IVS8 c.1245C87TOC NK J61
E39 c.2921COA* Pro446Glu J64
E59 c.4416COA* Asp944Glu J14
COL11A2 E17 c.1615COT* Arg53Trp J38
IVS42 c.31512delA* Deletion of e43
(36 amino acids)
Family EC
(Fig. 1)
E63 c.4590COT Thr1044Thr (NK) K136
*Studied in more detail.
yNK, not known.different heteroduplexes observed by CSGE analysis were
sequenced at least from one sample, and the control
samples were analysed for the presence of the observed
sequence variations. Altogether 239 sequence variations
were identiﬁed in the probands, 16 of which were not
present in the controls. Two of these variants unique to
affected individuals were in COL2A1, ﬁve in COL11A1,
three in COL11A2, two in COL9A1, one in COL9A2 and
three in COL9A3 (Table II). Seven of the variations, one in
COL2A1, four in COL11A1 and two in COL11A2, were
studied in more detail because they were predicted to result
in amino acid substitutions or cause splicing abnormalities,
and are described below.
COL2A1
The unique variation in COL2A1 was a c.2659GOA
change in the last nucleotide of exon 38, resulting in a silent
mutation (Table II). This was found in proband J35, who has
had OA symptoms since the age of 30 years, has
undergone replacement of the right hip and has Heberden’s
nodes. She does not have cleft palate or myopia, but has
a mild sensorineural hearing defect in the left ear. Her
sister, currently 80 years of age had also inherited the allele
[Fig. 3(A)]. She was diagnosed as having OA at 50 years of
age and now has OA in the knees, hands and left hip. She
does not have myopia, hearing defect or any other ﬁndings
typical of Stickler syndrome. As this mutation could
potentially affect splicing53, total RNA was extracted from
the EBV-transformed lymphoblasts of proband J35 and
from a control healthy individual, and analysed by RT-PCR.
Three separate RT-PCR reactions were performed, but only
one fragment, corresponding to the wild-type cDNA, was
obtained from each reaction both in proband J35 and in
control. Sequencing showed that only the wild-type allele,
the G allele, was found in two of the three cases, and both
the G and A alleles were present only in one cDNA sample.
This ﬁnding suggests that the G to A mutation causes
a quantitative or ‘‘leaky’’ splicing defect that results in
aberrant splicing and non-sense mediated mRNA decay,most likely by the use of a cryptic splice site in some but not
all mRNAs from the mutant allele.
COL11A2
A c.1615COT variation in exon 17 of COL11A2 that
converted a codon CGG for Arg53 to a codon TGG for Trp in
the major triple helix was found in proband J38 (Table II),
who had had OA symptoms since the age of 38 years. He
had undergone right hip replacement at the age of 54 years
and left hip replacement 9 years later. Since tryptophan is
not normally found in collagenous sequences and was not
found in any of the 103 controls or in the 100 random
population samples, family members of proband J38 were
included in the study [Fig. 3(B)]. Four additional family
members, II:7, II:8, II:9 and III:1, had inherited the Trp allele
[Fig. 3(B)]. Individual II:7 had had hip, knee and hand pain,
and she has Heberden’s nodes and radiologically con-
ﬁrmed hip, knee and hand OA. Individual II.8 has had hip
and hand pain and has spinal OA and Heberden’s nodes,
but with no radiological evidence of hip or knee OA.
Individual II.9 has had hip, knee and shoulder pain. A loose
cartilage fragment, caused by osteochondritis dissecans,
was removed from his left knee 10 years ago and the left
meniscus was repaired later. Currently, at the age of 47, he
has OA in the left knee and mild osteoarthritic changes in
the right knee (not shown). The son (III:1) of proband J38,
currently 45 years old, had had pain in the left knee.
Radiological and MRI examinations showed signs of
previous Osgood Schlatter disease in the right knee, but
no OA changes were present in the knees or hips. One
individual (II:4) in this family without the tryptophan allele
had OA. She was diagnosed as having bilateral hip OA at
the age of 65 years, much later than the individuals with the
Trp allele, and she has not had any other joint complaints or
radiological evidence of knee OA. Polyphen analysis based
on sequence alignment predicted this substitution to be
probably damaging, which was expected because of
a change of a highly conserved amino acid.
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A C to A change (c.2921) in exon 39 of COL11A1 that
was predicted to cause a Pro446Gln substitution was found
in proband J64. This variation was not present in the
controls or in the random population samples. The proband
had undergone replacement of the right hip at the age of 40
years, and his sister [Fig. 3(C)], who had also inherited the
allele, has bilateral hip and knee OA. Her daughter (II:4),
again with the allele, has bilateral knee OA. The affection
status of the four other family members who had the
sequence variation (II:1, II:6, II:7 and II:8) could not be
determined radiologically since they were not available for
radiological examination. Thus the ﬁndings from the family
studies suggest that this mutation associates with the
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Fig. 3. Family pedigrees of probands J35 (A), J38 (B) and J64 (C).
Black circles (females) and squares (males) indicate individuals
with radiologically conﬁrmed OA. The probands are denoted by
diagonal arrows, inherited gene alteration by a plus sign (C), and
an inherited normal allele by a minus () sign. Hatched circles and
squares indicate symptomatic individuals without radiological
information or evidence of OA. Asymptomatic, non-radiologically
examined individuals are indicated by open symbols. A question
mark (?) denotes unknown affection status. The ages of the
individuals are shown below the symbols.phenotype, although it is not likely to be fully penetrant.
Analysis of this substitution using Polyphen program
resulted in unknown status due to unavailability of data.
However, this substitution also affects a highly conserved
amino acid suggesting potential pathogenetic role.
Two nucleotide changes in COL11A1 that converted
Glu188 (c.1021GOC) to Gln and Asp944 (c.4416COA) to
Glu were found in proband J14, who has bilateral hip OA.
His mother and maternal grandmother had had a history of
OA, but DNA analysis could not be performed either on
them or on the father as they were deceased. The only
close relative available for testing was the proband’s
asymptomatic sister, and the analysis indicated that she
had not inherited the alleles. Even though these variations
were not present in the controls, one individual in the
random population was found to have the two variations,
a woman aged 52 years of age who had a history of hip pain
and for whom radiological examination revealed OA in the
left hip and mild osteoarthritic changes in the knees (not
shown). Polyphen analysis of these substitutions based on
alignment of sequences predicted both variants to be
benign even though substitutions occurred in conserved
amino acids. The evidence for their pathogenic role is
therefore limited and these variations could represent rare,
neutral polymorphisms.
A single nucleotide variation (c.139TOA) in exon 2 that
converted a codon TTT for Phe482 to a codon ATT for Ile
was found in COL11A1 in proband K123, with bilateral hip
OA. Co-segregation analysis could not be performed
because the family members refused to participate in the
study. None of the controls had this amino acid substitution,
but it was found once in the 100 random population
samples. This individual was a 37-year-old female who
had evidence of Osgood Schlatter disease in the left knee
and a traumatic meniscus lesion in the right knee, but no
evidence of OA in the knees. She also had a history of
lumbar disc herniation. Hip radiographs could not be
obtained. Polyphen analysis based on sequence alignment
predicted that substitution is possibly damaging.
COL9A1, COL9A2 and COL9A3
Altogether ﬁve unique intronic variations and one exonic
onewere found inCOL9A1,COL9A2 andCOL9A3 (Table II),
but none of them altered known splicing consensus
sequences or resulted in amino acid substitutions.
ALLELIC ASSOCIATION
Between six and 12 polymorphisms were chosen, on the
basis of being relatively common, for full genotyping in all
six examined collagen genes, applying to a total of 49 SNPs
and other polymorphic sites. The observed allele frequen-
cies were compared between the 72 unrelated Finnish
probands and the 103 unrelated Finnish controls. Fisher’s
‘‘exact’’ test was used to analyse the individual diallelic
polymorphisms, one polymorphism at a time. To verify that
the allele frequencies do not differ between the individuals
enrolled at Jyvaskyla¨ Central Hospital and Kuopio Univer-
sity Hospital, negative control analyses were conducted
between probands from both hospitals and between
controls from both hospitals. No evidence for a genetic
difference between individuals from these regions was
obtained, and the individuals from both regions were thus
combined. No statistically signiﬁcant differences in allele
frequencies (after adjusting for multiple testing) were
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Allele frequencies and P-values of the 49 genotyped polymorphisms
Gene Polymorphism MOmy Allele frequency*
Patients (nZ 72) Controls (nZ 103) P
COL2A1 c.504COA (Gly33Gly)z 0.15 (122/22) 0.20 (165/41) 0.323
c.762C15GOA 0.41 (85/59) 0.39 (126/80) 0.739
c.762C42del G 0.17 (119/25) 0.22 (160/46) 0.282
c.152861COT 0.31 (99/45) 0.35 (133/73) 0.424
c.2409C83GOC 0.26 (106/38) 0.33 (137/69) 0.160
c.407514COG 0.10 (130/14) 0.08 (190/16) 0.563
COL9A1 c.8912TOC 0.20 (115/29) 0.17 (170/36) 0.577
c.30067_69del GGG 0.07 (134/10) 0.07 (191/15) 1.000
c.1230C12TOC 0.24 (110/34) 0.17 (171/35) 0.135
c.1230C143AOG 0.50 (72/72) 0.48 (106/98) 0.745
c.172024AOC 0.40 (86/58) 0.42 (119/87) 0.742
c.1728TOG (Pro1783Pro)x 0.03 (140/4) 0.04 (198/8) 0.768
c.2034C19TOC 0.23 (109/33) 0.17 (172/34) 0.129
c.2259C32TOC 0.51 (71/73) 0.48 (107/99) 0.664
c.2259C55COG 0.17 (119/25) 0.24 (157/49) 0.183
COL9A2 c.303C26GOA 0.28 (104/40) 0.27 (150/56) 0.904
c.3648COT 0.02 (141/3) 0.02 (201/5) 1.000
c.36416AOC 0.27 (105/39) 0.22 (161/45) 0.309
c.36420AOG 0.02 (141/3) 0.02 (201/5) 1.000
c.9554COG 0.05 (137/7) 0.04 (197/9) 1.000
c.128812COT 0.02 (141/3) 0.02 (201/5) 1.000
c.1323C24COT 0.01 (142/2) 0.02 (202/4) 1.000
c.1368C16AOG 0.05 (137/7) 0.04 (197/9) 1.000
c.160427insCTCC 0.04 (138/6) 0.04 (197/9) 1.000
c.1741GOA (Pro581Ile) 0.05 (137/7) 0.04 (197/9) 1.000
c.1793C17GOA 0.03 (140/4) 0.02 (201/5) 1.000
c.2001COT (Ala667Ala) 0.06 (135/9) 0.08 (190/16) 0.676
COL9A3 c.209COT (Pro70Leu) 0.06 (136/8) 0.05 (195/11) 1.000
c.34622GOA 0.10 (130/14) 0.08 (189/17) 0.703
c.900C38COT 0.19 (117/27) 0.15 (175/31) 0.383
c.12885TOC 0.34 (95/49) 0.35 (134/72) 0.909
c.1304COA (Ala435Glu) 0.17 (120/24) 0.20 (165/41) 0.487
c.1740COT; (Pro580Pro) 0.29 (102/42) 0.33 (137/69) 0.416
c.178767AOG 0.12 (127/17) 0.08 (190/16) 0.264
c.2044COA (Arg682Arg) 0.11 (128/16) 0.07 (191/15) 0.253
COL11A1 c.135176AOG 0.31 (100/44) 0.31 (142/64) 1.000
c.179238_36insTGA 0.17 (119/25) 0.17 (172/34) 0.885
c.302523AOT 0.17 (120/24) 0.13 (180/26) 0.352
c.3968TOC (Leu795Pro) 0.32 (98/46) 0.32 (141/65) 1.000
c.3978C38TOG 0.19 (116/28) 0.14 (178/28) 0.182
c.4512COT (Gly976Gly) 0.19 (117/27) 0.16 (173/33) 0.565
c.4770COT (Ile1062Ile) 0.37 (91/53) 0.35 (134/72) 0.735
COL11A2 c.8774TOA 0.25 (108/36) 0.24 (157/49) 0.801
c.1179C10GOA 0.14 (124/20) 0.13 (180/26) 0.750
c.2430C51COG 0.27 (105/39) 0.35 (134/72) 0.130
c.2681COT (Pro408Leu) 0.14 (124/20) 0.14 (178/28) 1.000
c.3174GOA (Pro572Pro) 0.39 (88/56) 0.35 (134/72) 0.499
c.385339GOA 0.49 (73/71) 0.48 (108/98) 0.828
c.433949TOG 0.34 (95/49) 0.36 (131/75) 0.733
*Allele frequency of the less common allele in controls, the allele counts of each group are in parentheses (major allele/minor allele), for
deletions and insertions the ﬁrst number in parentheses refers to normal variant without deletion or insertion.
yMZmajor, common allele in controls; mZminor, less common allele in controls.
zFor COL2A1, COL11A1 and COL11A2 amino acids are numbered from the beginning of the major triple-helical region of each gene.
xFor COL9A1, COL9A2 and COL9A3 amino acids are numbered from the translation initiation site.detected between the probands and controls at any site in
any gene, either when considering all the affected subjects
(Table III) or when subdividing them into cases of OA of the
knee or the hip (data not shown). Stratiﬁcation of the data
set by sex showed a marginal difference in the allele
frequencies of two SNPs (c.302523AOT, P 0.028;
c.4512COT, P 0.033) in COL11A1 between the femalecases and controls, but when multiple testing was taken into
account these differences were no longer signiﬁcant.
Discussion
Epidemiological, linkage and association studies have
provided a vast amount of evidence for a signiﬁcant genetic
504 E. Jakkula et al.: Cartilage collagens and osteoarthritiscontribution to primary OA1,4e8, but the major susceptibility
genes have not been determined yet. Even though there is
some support for a role of cartilage collagens in primary OA,
little direct evidence is available11,21e25,36,37,54. To address
this issue, we performed a systematic mutation and
association analysis.
Altogether 16 unique sequence variations were found in
the cartilage collagen genes in 13 probands. Seven of the
variations, found in six probands, were studied in more
detail, because they were predicted to result in either
splicing defects or substitutions of conserved amino acids.
To further ascertain the role of the sequence variations in
OA, members of the families of ﬁve of the six probands
were examined. Co-segregation of the sequence variation
and the phenotype was observed in four of these families,
while the ﬁfth could not be assessed because the parents of
the proband were deceased and the only close relative
available for testing was proband’s unaffected sister who
did not have these variants. One individual in the random
population was found to have the two variations, however,
clinical and radiological examinations revealed that she also
had OA, suggesting some signiﬁcance of these variations
for the disease. As in other complex diseases, these
families with potential disease causing variants may
represent the rare Mendelian, early-onset form of osteoar-
thritis. To estimate the proportion of OA cases due to these
observed variants or the risk they cause requires study
using larger patient and control material.
It is likely that there are mild CD cases that will go
undiagnosed if no clinical attention is required during
childhood, but these may be expressed as OA later in life.
Even though dysplastic changes may be evident in child-
hood, they tend to diminish with the age. This is especially
true of a particular MED type, which is caused by collagen
IX mutations. It is also possible that some OA cases
represent the mild end of the CD phenotypic spectrum,
a hypothesis that is supported by observations that some
mutations in cartilage collagen genes result in OA associ-
ated with very mild CD11,54. To corroborate this statement,
we observed certain mutation types that have previously
been mainly associated with various CDs. One of them was
a G to A change in the last nucleotide of exon 38 of
COL2A1, resulting in a splicing defect and non-sense
mediated mRNA decay. COL2A1 haploinsufﬁciency typi-
cally causes Stickler syndrome, which is characterised by
cleft palate, high myopia, vitreoretinal degeneration, retinal
detachment, sensorineural hearing loss and arthropathy11.
The two affected family members who had the mutation had
primary OA but no other ﬁndings typical of Stickler
syndrome. This is best explained by the observation made
here that the splicing mutation was leaky and resulted in
a partial reduction of mRNA from the mutant allele, but not
in haploinsufﬁciency. The signiﬁcance of this ﬁnding is
supported by the report of Loughlin et al.24, who showed
that reduced expression of one of the COL2A1 alleles can
contribute to the development of OA.
Another example was a splicing mutation, c.3151-2delA,
in intron 42 of COL11A2 that resulted in the skipping of exon
43 and thus an in-frame deletion of 108 bp. Three mutations
leading to in-frame deletions of 27 or 54 bp in COL11A2
have previously been found in patients with non-ocular
Stickler syndrome39,55,56, but this larger deletion may have
different consequences, a hypothesis supported by the
ﬁndings that Kniest dysplasia is caused by deletions of
54 bp or smaller in COL2A157. Weis et al.58 showed that
a1(II) chains containing deletions of 18 residues or less
were able to incorporate into collagen II molecules, resultingin looping out of the normal chains at the site of deletion
with the maintenance of chain registration and a normal
amino-terminal structure. Because the deletion found here
was signiﬁcantly larger, 108 bp, it is possible that the
affected a2(XI) chains are unable to maintain registration of
the a1(XI) and a3(XI) chains and lead to only partially
folded molecules.
We also identiﬁed an Arg53Trp mutation in the a2(XI)
chain in one family. Tryptophan is not normally present in
the triple-helical domains of collagens, but two Trp
mutations in collagen IX have previously been reported to
be associated with a common human disease, lumbar disc
disease59,60. To the best of our knowledge, Trp substitu-
tions have not been reported as neutral variants in
collagens. It is possible that Trp, the most hydrophobic
amino acid, has an effect on the triple-helix conformation or
interactions with other matrix molecules59,60.
We initially considered collagen IX to be one of the
strongest candidates for OA, because mutations in it,
resulting in MED, are typically associated with knee OA in
adults28e35. Results of transgenic and knockout mouse
studies have also implicated collagen IX in OA36,37. None of
the six unique sequence variations in collagen IX genes
identiﬁed here resulted in any obvious alteration in protein
structure. Even though the possibility that some of the
variations may alter regulatory sequences or intronic or
exonic splicing elements61 cannot be excluded, no role for
collagen IX mutations in OA could be demonstrated. This
conclusion is supported by the ﬁndings of a recent
comprehensive association study, which did not provide
any evidence for COL9A1 as the locus of OA suscep-
tibility62. The role of variations in genes encoding collagen
XI are supported by the mouse model, in which mice
heterozygous for a loss-of-function mutation in Col11a1
developed osteoarthritis earlier than their wild-type
littermates42.
Each of the cartilage collagen genes was found to have
numerous polymorphisms, and suitable highly polymorphic
SNPs or other polymorphisms were available for association
analysis in all except COL9A2, which had only a few highly
polymorphic sites, even though numerous polymorphisms
were present in a small subset of patients and controls.
Several association studies of COL2A1 and OA have been
performed using a few SNPs, but the results have been
somewhat contradictory8. However, based on those studies
and the results from this study it seems obvious that
COL2A1 variations are not the major factors in OA. An
association study by Japanese group found association with
a SNP in COL9A3 and female OA63. The same SNP
(c.1740COT) was analysed in this study, but no association
was found in the Finnish subjects. An association with
intronic variation (c.8774TOA) leading to splicing abnor-
mality in COL11A2 have been reported in Japanese
ossiﬁcation of posterior longitudinal ligament patients and
in Finnish spinal stenosis patients64,65. Even though both of
these disorders are degenerative in nature, no association
was found with OA phenotype and this variant in this study.
However, our sample size was quite small decreasing our
power to detect common, low-risk alleles.
Given the lack of evidence for an allelic association at the
level of individual polymorphisms, the absence of phase
information from pedigree data and our relatively small
sample size, we did not attempt to estimate haplotype
frequencies for all the polymorphisms genotyped in a given
collagen gene, nor to compare them between the probands
and controls. Instead, to strengthen our conﬁdence that we
had not overlooked any differences between the probands
505Osteoarthritis and Cartilage Vol. 13, No. 6and controls in these genes, we used the multiple two-point
approach for joint analysis of the genotyped polymorphisms
within a gene52. While this approach is intended for more
distant marker locidit models the decay in linkage
disequilibrium as a function of inter-marker recombination
fractions, which are extremely small for intragenic sites, and
assumes a ‘‘background’’ linkage equilibrium among
marker loci, which is unrealistic for intragenic sitesdwe
expected that this approach would nonetheless provide
evidence of allelic association if the allele frequencies do in
fact differ between probands and controls. In agreement
with our single site analyses, no statistically signiﬁcant
result was obtained (data not shown). Although no common
predisposing alleles were found in any of the genes in the
association analysis, the mutation screening identiﬁed rare
unique variants in the collagen II and XI genes. This
suggests that future screenings for plausible candidate
genes should not merely focus on association studies.
In conclusion, the results presented here indicate that
sequence variations in the genes for collagen II, and more
especially collagen XI, may contribute to the pathogenesis
of early-onset OA, which is often considered to be an
oligogenic disease8. Our results suggest, and are sup-
ported by the views of Reginato and Olsen11, that OA may
consist of a group of distinct but overlapping phenotypes,
and that the number of genes and alleles within a gene
involved in its pathogenesis may well be higher than is
currently thought. This conclusion is further supported by
a recent report indicating that about 2% of Icelandic hand
OA patients have a mutation in the gene for matrilin-366.
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